-
Whole-exome sequencing data of ovarian clear cell carcinoma in East Asia
Study
EGAS50000000031
-
Genome-wide cell-free DNA fragmentation in patients with cancer
Study
EGAS00001003611
-
Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens
Study
EGAS00001005786
-
Distinct evolutionary trajectories of primary high grade serous ovarian cancers revealed through spatial mutational profiling
Study
EGAS00001000547
-
DirectHRD Enables Sensitive Scar-Based Classification of Homologous Recombination Deficiency (HRD)
Study
phs003760
-
Multiomics Characterization of Low-grade Serous Ovarian Carcinoma
Study
EGAS00001004724
-
Identification of Cancer Predisposition Genes in Breast Cancer Families
Study
phs000480
-
The Genomic Landscape of Interval Colorectal Cancers
Study
phs003093
-
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
Study
EGAS50000001069
-
Implementation, Adoption, and Utility of Family History in Diverse Care Settings
Study
phs001641
-
microRNA and isomiR profiling of Stage 1 epithelial ovarian carcinoma
Study
EGAS00001006617
-
DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded (FFPE) tissues followed by targeted sequencing
Study
EGAS50000001327
-
Phase Ib of olaparib and capivasertib
Study
EGAS00001004930
-
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Study
EGAS00001005984
-
Rapid identification of somatic genome rearrangements as personalized biomarkers for blood-based cancer monitoring
Study
EGAS00001003963
-
Surveillance, Epidemiology and End Results (SEER) Formalin Fixed Paraffin Embedded (FFPE) Tissue Feasibility Study
Study
phs000950
-
Direct Detection of Early-stage Cancers Using Circulating Tumor DNA
Study
EGAS00001002577
-
Single-cell RNA-seq data from metastatic ovarian cancer for quality control study
Study
EGAS00001005066
-
DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded (FFPE) tissues followed by shallow whole genome sequencing
Study
EGAS50000001328
-
The Breast and Prostate Cancer Cohort Consortium (BPC3) GWAS of Aggressive Prostate Cancer and ER- Breast Cancer
Study
phs000812
-
Single nucleus RNA sequencing of squamous cell carcinoma arising from mature teratoma of the ovary
Study
JGAS000521
-
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
Study
EGAS00001004366
-
The phase II Neo-Pembro trial: neoadjuvant pembrolizumab in stage IV high-grade serous ovarian cancer
Study
EGAS50000000781
-
Somatic mutations in endometriosis and normal uterine endometrium
Study
EGAS00001003095
-
Epigenetic Control of Topoisomerase 1 by MacroH2A1.1
Study
phs003729
-
Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway
Study
EGAS50000000136
-
High-Risk Breast Cancer GWAS
Study
phs000929
-
Eribulin efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
Study
EGAS50000000152
-
Limited Association between HRR Gene Alterations and HRD in Molecular Tumor Board Cancer Samples: Who should be tested for HRD?
Study
EGAS00001008063
-
RNA-seq of DF149 cells – a patient-derived xenograft model of ascites-derived, homologous recombination repair-proficient, high-grade serous ovarian carcinoma – cultured in vitro and isolated after 8 hours treatment with DMSO control (3 x biological replicates) and 2.5 µM CBL0137 (3 x biological replicates)
Study
EGAS00001006662
-
Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness
Study
EGAS00001003427
-
Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency
Study
EGAS00001002200
-
Probabilistic cell type assignment of single-cell transcriptomic data reveals spatiotemporal microenvironment dynamics in human cancers
Study
EGAS00001003452
-
Predicting resistance to chemotherapy using chromosomal instability signatures
Study
EGAS50000000992
-
Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas (COH_TNBC_RNAseq)
Study
EGAS00001006002
-
scRNA-seq of HGSC tumor and ascites
Study
EGAS00001004829
-
Systematic Growth Factor Profiling Platform for 3D Tumor Models Reveals EstradiolResponsive Cellular Mechanisms of Immunotherapy Resistance
Study
EGAS50000000422
-
A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genes
Study
phs003348
-
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
Study
EGAS50000000426
-
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Study
EGAS00001003119
-
High-grade serous ovarian cancer refined with single-cell RNA-sequencing
Study
EGAS00001004987
-
RNA sequencing data of 66 matched primary and recurrent high grade serous ovarian cancer
Study
EGAS00001002660
-
National Cancer Institute (NCI) Prostate Cancer Genome-Wide Association Study for Uncommon Susceptibility Loci (PEGASUS)
Study
phs000882
-
Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) - OncoArray Genotypes
Study
phs001265
-
National Institutes of Health The Cancer Genome Atlas (TCGA)
Study
phs000178
-
Expression Quantitative Trait Locus Mapping Studies in Mid-Secretory Phase Endometrial Cells Identifies HLA-F and TAP2 as Fecundability-Associated Genes
Study
phs001146
-
Molecular Analysis of Short- Versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma
Study
phs003020
-
The genomic landscape of early stage ovarian high grade serous carcinoma
Study
EGAS00001005567
-
Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes
Study
EGAS00001004235
-
The evolution of ovarian high grade serous carcinoma from STIC lesions
Study
EGAS50000000360